Boothbay Fund Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Boothbay Fund Management’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-43,790	Closed	-$14K	–	2759
2022 Q3	$14K	Sell	43,790 -4,607	-10%	-$1.31K	﹤0.01%	2175
2022 Q2	$12K	Hold	48,397	–	–	﹤0.01%	2193
2022 Q1	$34K	Hold	48,397	–	–	﹤0.01%	2218
2021 Q4	$40K	Hold	48,397	–	–	﹤0.01%	1785
2021 Q3	$66K	Sell	48,397 -9,453	-16%	-$12.8K	﹤0.01%	1831
2021 Q2	$90K	Sell	57,850 -35,561	-38%	-$49.6K	﹤0.01%	1751
2021 Q1	$147K	Buy	+93,411	New	+$161K	0.01%	1426

Boothbay Fund Management's MITO Position: Q4 2022 in Review

Boothbay Fund Management sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2022, closing a stake of 43,790 shares — an estimated $14K sold.

Boothbay Fund Management first reported a position in MITO in Q1 2021 and held it in 7 quarters. The position peaked at $147K in Q1 2021. 0 funds tracked by Wall St. Rank hold MITO as of Q4 2022.

Boothbay Fund Management reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 43,790 Stealth BioTherapeutics Corp. ADS shares in Q4 2022, an estimated $14K.
Boothbay Fund Management first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2021 and held it in 7 quarters.
Boothbay Fund Management's Stealth BioTherapeutics Corp. ADS position peaked at $147K in Q1 2021.
0 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.